TY - JOUR
T1 - Identification of acute respiratory distress syndrome subphenotypes de novo using routine clinical data
T2 - A retrospective analysis of ARDS clinical trials
AU - Duggal, Abhijit
AU - Kast, Rachel
AU - Van Ark, Emily
AU - Bulgarelli, Lucas
AU - Siuba, Matthew T.
AU - Osborn, Jeff
AU - Rey, Diego Ariel
AU - Zampieri, Fernando G.
AU - Cavalcanti, Alexandre Biasi
AU - Maia, Israel
AU - Paisani, Denise M.
AU - Laranjeira, Ligia N.
AU - Serpa Neto, Ary
AU - Deliberato, Rodrigo Octávio
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2022/1
Y1 - 2022/1
N2 - Objectives The acute respiratory distress syndrome (ARDS) is a heterogeneous condition, and identification of subphenotypes may help in better risk stratification. Our study objective is to identify ARDS subphenotypes using new simpler methodology and readily available clinical variables. Setting This is a retrospective Cohort Study of ARDS trials. Data from the US ARDSNet trials and from the international ART trial. Participants 3763 patients from ARDSNet data sets and 1010 patients from the ART data set. Primary and secondary outcome measures The primary outcome was 60-day or 28-day mortality, depending on what was reported in the original trial. K-means cluster analysis was performed to identify subgroups. Sets of candidate variables were tested to assess their ability to produce different probabilities for mortality in each cluster. Clusters were compared with biomarker data, allowing identification of subphenotypes. Results Data from 4773 patients were analysed. Two subphenotypes (A and B) resulted in optimal separation in the final model, which included nine routinely collected clinical variables, namely heart rate, mean arterial pressure, respiratory rate, bilirubin, bicarbonate, creatinine, PaO 2, arterial pH and FiO 2. Participants in subphenotype B showed increased levels of proinflammatory markers, had consistently higher mortality, lower number of ventilator-free days at day 28 and longer duration of ventilation compared with patients in the subphenotype A. Conclusions Routinely available clinical data can successfully identify two distinct subphenotypes in adult ARDS patients. This work may facilitate implementation of precision therapy in ARDS clinical trials.
AB - Objectives The acute respiratory distress syndrome (ARDS) is a heterogeneous condition, and identification of subphenotypes may help in better risk stratification. Our study objective is to identify ARDS subphenotypes using new simpler methodology and readily available clinical variables. Setting This is a retrospective Cohort Study of ARDS trials. Data from the US ARDSNet trials and from the international ART trial. Participants 3763 patients from ARDSNet data sets and 1010 patients from the ART data set. Primary and secondary outcome measures The primary outcome was 60-day or 28-day mortality, depending on what was reported in the original trial. K-means cluster analysis was performed to identify subgroups. Sets of candidate variables were tested to assess their ability to produce different probabilities for mortality in each cluster. Clusters were compared with biomarker data, allowing identification of subphenotypes. Results Data from 4773 patients were analysed. Two subphenotypes (A and B) resulted in optimal separation in the final model, which included nine routinely collected clinical variables, namely heart rate, mean arterial pressure, respiratory rate, bilirubin, bicarbonate, creatinine, PaO 2, arterial pH and FiO 2. Participants in subphenotype B showed increased levels of proinflammatory markers, had consistently higher mortality, lower number of ventilator-free days at day 28 and longer duration of ventilation compared with patients in the subphenotype A. Conclusions Routinely available clinical data can successfully identify two distinct subphenotypes in adult ARDS patients. This work may facilitate implementation of precision therapy in ARDS clinical trials.
KW - adult intensive & critical care
KW - respiratory medicine (see thoracic medicine)
UR - http://www.scopus.com/inward/record.url?scp=85122912000&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2021-053297
DO - 10.1136/bmjopen-2021-053297
M3 - Article
C2 - 34992112
AN - SCOPUS:85122912000
VL - 12
JO - BMJ Open
JF - BMJ Open
SN - 2044-6055
IS - 1
M1 - e053297
ER -